Business Wire

AUTOFLEET/BLUEBIRD/ABEAM

22.4.2021 15:02:11 CEST | Business Wire | Press release

Share
Bluebird Partners With Autofleet and ABeam to Optimize and Scale One of Asia’s Largest Taxi Fleets

Bluebird Group (Bluebird), Indonesia’s leading taxi operator, has engaged with Autofleet and ABeam Consulting for a project to support its national fleet of over 23,000 vehicles with Autofleet’s Vehicle-as-a-Service platform. Bluebird and Autofleet have entered into a commercial agreement that is scheduled to roll out for vehicles operating in Jakarta and the surrounding area as soon as Q2 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005276/en/

By leveraging the Autofleet platform, Bluebird will be able to optimize its fleet’s vehicle placement, match and predict drivers based on demand forecasting to reduce empty rides, optimize allocation efficiency, allow for greater availability in traditionally under-served areas, reduce customer ETAs and improve overall customer experience. Autofleet is ingesting data from rides requested through the operator’s digital app and through traditional street hailing. These inputs are combined with real-time traffic data, weather forecasts, local events and other data points for increased demand prediction accuracy.

“The demand for mobility services has evolved, and it poses challenges that can only be solved by a combination of AI driven technology, and best in class operations. It is Bluebird’s value and commitment to deliver such customer-centric innovation through sustainable cooperation with our strategic partners, Autofleet and ABeam Consulting,” said Paul Soegianto, Chief Strategy Officer of PT Blue Bird Tbk.

In business for nearly 50 years, Bluebird serves millions of passengers every month. The fleet includes regular taxis (Bluebird & Pusaka), executive taxis (Silverbird), limousines and car rentals (Goldenbird), bus charters (Bigbird) and logistics (Birdkirim) among others. Autofleet’s platform will be integrated into the current dispatch infrastructure, supporting Bluebird, Silverbird and Birdkirim services in its first phase. In the longer term, the collaboration will inform Bluebird’s expanded activities in logistics and delivery services as well as exploration of new mobility infrastructure including electric vehicle (EV) charging.

“We are excited to partner with Bluebird, already a leader in mobility services in Southeast Asia, and apply the Autofleet platform to power current operations and prepare the business for future strategy and growth,” said Kobi Eisenberg, CEO at Autofleet. “Deploying Autofleet's platform will keep Bluebird at the cutting edge of the mobility industry, providing an outstanding customer experience, in a very competitive market.”

“ABeam Consulting is thrilled to support and expand Bluebird’s innovative services through AI and machine learning to increase operational efficiency,” said Tatsuya Kamoi, CEO at ABeam Consulting. “With our deep expertise in Mobility as a Service, we will support Bluebird’s operations and apply industry best practices to stay competitive with leading rideshare companies.”

In September 2020, Autofleet and ABeam Consulting entered a partnership to offer a comprehensive solution that supports Mobility as a Service (MaaS) projects end-to-end from the proposal stage to system implementation. Following projects in Japan and Cambodia, the engagement with Bluebird was secured through a year-long competitive proposal process and represents the largest commercial fleet management opportunity arising from the partnership to date.

About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/ .

About ABeam Consulting
ABeam Consulting Ltd., headquartered in Tokyo having 6,600 people serve more than 1,100 clients throughout Asia, in the Americas and Europe with its 28 offices since 1981, providing consulting services across various industries and with an expertise in digital transformation services that create strategic advantage, improve business processes, leverage technology innovation and enhance organizational performance.

Please contact and visit us under https://www.abeam.com/jp/en for more details.

About Bluebird
Established in 2001, PT Blue Bird Tbk (BIRD), is a public transportation company catering to passengers and providing other land transportation services. PT Blue Bird Tbk's 15 subsidiaries are found in 18 major cities around the country, namely Jakarta, Depok, Tangerang, Bekasi, Cilegon, Medan, Manado, Bandung, Palembang, Balikpapan, Padang, Pangkalpinang, Batam, Bali, Lombok, Semarang, Surabaya, Pekanbaru, Makassar, Solo and Yogyakarta.

Bluebird is committed to always provide safe, reliable, and comfortable transportation with easy accessibility for its customers. Companies extensive network covers more than 600 exclusive taxi outlets placed in malls, shopping centers and other strategic places. Serving millions of passengers every month.

Since going public on the Indonesia Stock Exchange in 2014, PT Blue Bird Tbk has gained status as a reliable and trustworthy transportation partner.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye